Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis

Journal of Trauma - Injury, Infection and Critical Care

Volumn 71, Issue 2, 2011, Pages 375-379

  Cotton, Bryan A ^a   Kao, Lillian S ^a   Kozar, Rosemary ^a   Holcomb, John B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Brain injury; Fosphenytoin; Levetiracetam; Phenytoin; Seizure

Indexed keywords

ETIRACETAM; FOSPHENYTOIN SODIUM; PHENYTOIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; GLASGOW OUTCOME SCALE; HUMAN; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SEIZURE; SENSITIVITY ANALYSIS; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; BRAIN INJURIES; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PIRACETAM; SEIZURES; TREATMENT OUTCOME;

EID: 80051770295     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e318224d307     Document Type: Article

References (35)

1. De Silva MJ, Roberts I, Perel P, et al. Patient outcome after traumatic brain injury in high-, middle-and low-income countries: analysis of data on 8927 patients in 46 countries. Int J Epidemiol. 2009;38:452-458.
2. Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia. 2003;44(Suppl 10):11-17. (Pubitemid 37280387)
3. Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009;50(Suppl 2):10-13.
4. Dasgupta AK. Post-traumatic epilepsy: its complications and impact on occupational rehabilitation-an epidemiological study from India. Occup Med (Lond). 1998;48:487-495. (Pubitemid 29039115)
5. Teasdale TW, Engberg AW. Subjective well-being and quality of life following traumatic brain injury in adults: a long-term population-based follow-up. Brain Inj. 2005;19:1041-1048. (Pubitemid 41701026)
6. Engberg AW, Teasdale TW. Psychosocial outcome following traumatic brain injury in adults: a long-term population-based follow-up. Brain Inj. 2004;18:533-545. (Pubitemid 38584631)
7. So EL, Bainbridge J, Buchhalter JR, et al. Report of the American Epilepsy Society and the Epilepsy Foundation joint task force on sudden unexplained death in epilepsy. Epilepsia. 2009;50:917-922.
8. Haltiner AM, Temkin NR, Winn HR, Dikmen SS. The impact of posttraumatic seizures on 1-year neuropsychological and psychosocial outcome of head injury. J Int Neuropsychol Soc. 1996;2:494-504. (Pubitemid 126449815)
9. Dijkers MP. Quality of life after traumatic brain injury: a review of research approaches and findings. Arch Phys Med Rehabil. 2004;85:S21-S35. (Pubitemid 38857932)
10. McNamara B, Ray J, Menon D, Boniface S. Raised intracranial pressure and seizures in the neurological intensive care unit. Br J Anaesth. 2003;90:39-42. (Pubitemid 36113620)
11. Chang BS, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;60:10-16. (Pubitemid 36070636)
12. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma. 2007;24(Suppl 1):S83-S86.
13. Faul M, Wald MM, Rutland-Brown W, Sullivent EE, Sattin RW. Using a cost-benefit analysis to estimate outcomes of a clinical treatment guideline: testing the Brain Trauma Foundation guidelines for the treatment of severe traumatic brain injury. J Trauma. 2007;63:1271-1278.
14. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323:497-502. (Pubitemid 20260049)
15. Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, Tsankov N. Toxic epidermal necrolysis as a dermatological manifestation of drug hypersensitivity syndrome. Eur J Dermatol. 2007;17:422-427. (Pubitemid 47425910)
16. McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care. 2009;10:222-224.
17. Szaflarski JP, Meckler JM, Szaflarski M, Shutter LA, Privitera MD, Yates SL. Levetiracetam use in critically ill patients. Neurocrit Care. 2007;7:140-147. (Pubitemid 350242663)
18. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 12:165-172.
19. Jones KE, Puccio AM, Harshman KJ, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008;25:E3.
20. Teasdale TW, Engberg AW. Disability pensions in relation to traumatic brain injury: a population study. Brain Inj. 2000;14:363-372. (Pubitemid 30209425)
21. Wang HC, Chang WN, Chang HW, et al. Factors predictive of outcome in posttraumatic seizures. J Trauma. 2008;64:883-888.
22. Lawn ND, Bamlet WR, Radhakrishnan K, O'Brien PC, So EL. Injuries due to seizures in persons with epilepsy: a population-based study. Neurology. 2004;63:1565-1570. (Pubitemid 39507570)
23. Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: costeffectiveness in refractory epilepsy. Clin Drug Investig. 2003;23:225-232. (Pubitemid 36469960)
24. Dooley M, Plosker GL. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs. 2000;60:871-893.
25. Vespa PM, O'Phelan K, Shah M, et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology. 2003;60:1441-1446. (Pubitemid 36554803)
26. Ronne-Engstrom E, Winkler T. Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity. Acta Neurol Scand. 2006;114:47-53. (Pubitemid 43873524)
27. Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg. 1999;91:750-760. (Pubitemid 30053146)
28. Day SM, Wu YW, Strauss DJ, Shavelle RM, Reynolds RJ. Causes of death in remote symptomatic epilepsy. Neurology. 2005;65:216-222. (Pubitemid 41022364)
29. Hesdorffer DC, D'Amelio M. Mortality in the first 30 days following incident acute symptomatic seizures. Epilepsia. 2005;46(Suppl 11):43-45. (Pubitemid 44922037)
30. Logroscino G, Hesdorffer DC, Cascino G, et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia. 2005;46(Suppl 11):46-48. (Pubitemid 44922038)
31. Boucher BA, Rodman JH, Fabian TC, et al. Disposition of phenytoin in critically ill trauma patients. Clin Pharm. 1987;6:881-887. (Pubitemid 17162997)
32. Boucher BA, Rodman JH, Jaresko GS, Rasmussen SN, Watridge CB, Fabian TC. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther. 1988;44:675-683. (Pubitemid 19036620)
33. Tisdall M, Russo S, Sen J, et al. Free phenytoin concentration measurement in brain extracellular fluid: a pilot study. Br J Neurosurg. 2006;20:285-289. (Pubitemid 44863787)
34. Fierro LS, Savulich DH, Benezra DA. Safety of fosphenytoin sodium. Am J Health Syst Pharm. 1996;53:2707-2712. (Pubitemid 26386654)
35. Haltiner AM, Newell DW, Temkin NR, Dikmen SS, Winn HR. Side effects and mortality associated with use of phenytoin for early posttraumatic seizure prophylaxis. J Neurosurg. 1999;91:588-592. (Pubitemid 30133455)